Johnson & Johnson could obtain late-stage trial results of a COVID-19 vaccine it is developing earlier than expected, its chief scientist, Paul Stoffels, said on Tuesday. Results are expected in late January. The US company last month said it was hoping to have all the data needed to seek U.S. authorisation by February or earlier.
This development has added to the optimism about covid vaccine rollouts after UK became the first country on Tuesday to administer Pfizer covid vaccines.
Johnson & Johnson’s covid vaccine candidate is a single-dose vaccine, whereas the vaccines from Moderna and Pfizer and another under development by AstraZeneca all require two shots several weeks apart.
Johnson & Johnson also said it plans to provide 500 million doses of its vaccine for poor countries once results of clinical trials are announced by the end of January.
It plans to sell the vaccine at cost price and will provide the doses to Gavi, the Vaccine Alliance, the group’s scientific director Paul Stoffels told a virtual round table in Geneva.